EREG and carcinoma: Beyond genomic/epigenetic alterations of oncogenes and/or tumor suppressors, the epidermal growth factor receptor (EGFR) ligand EREG can function as a bona fide biomarker of therapeutic sensitivity for many EGFR-driven carcinomas [10].